Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
huCD33-BsAb
- Development stage
- Discontinued
- Lead developer
- Y-mAbs Therapeutics
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Parenteral
01
Overview
**huCD33-BsAb** is a humanized bispecific monoclonal antibody developed by Y-mAbs Therapeutics (a subsidiary of SERB) originating from Memorial Sloan-Kettering Cancer Center. It targets **CD33** on myeloid leukemia cells and **CD3** on T cells, redirecting T-cell cytotoxicity to induce **antibody-dependent cell cytotoxicity (ADCC)** while inhibiting CD33 and stimulating T lymphocytes. Primarily investigated for **acute myeloid leukemia (AML)** in adults, adolescents, and children (second-line or greater) and broader **hematological malignancies**, development reached **Phase I** but was **suspended** by late 2024 due to business priorities, with a terminated trial (NCT05077423).[1][7]
- Other names
- huCD33-Bispecific antibody - Y-mAbs TherapeuticshuCD-33-Bispecific antibody - Y-mAbs TherapeuticshuCD 33-Bispecific antibody - Y-mAbs Therapeutics
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on huCD33-BsAb.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on huCD33-BsAb.